Myricx Bio Announces Appointment of Paolo Paoletti MD as an Independent Non Executive Director
October 07, 2024 04:46 ET
|
Myricx Bio
LONDON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates...
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
July 08, 2024 02:00 ET
|
Myricx Bio
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated...
Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
November 27, 2023 11:00 ET
|
Myricx Bio
Data published today in Nature Cell Biology by Myricx collaborators at the MRC-LMS (Laboratory of Medical Sciences) led by Prof. Jesús Gil have uncovered the central role of N-myristoyltransferase...
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
November 21, 2023 04:00 ET
|
Myricx Bio
LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug...
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
November 15, 2023 03:00 ET
|
Myricx Bio
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads...
Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class
October 17, 2023 07:00 ET
|
Myricx Bio
Preclinical efficacy studies validate Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) payload platformComplete tumour regressions across a range of solid tumour xenograft models for...
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
October 04, 2023 04:00 ET
|
Myricx Bio
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for...
Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
September 13, 2023 04:00 ET
|
Myricx Bio
LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for...
Myricx Enters into Antibody License Agreement with Biocytogen
September 07, 2023 07:00 ET
|
Myricx Bio
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for...
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
April 17, 2023 13:30 ET
|
Myricx Pharma
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload...